- Correspondence on Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
-
Yeo YH, Yang JD
- KMID: 2549392
- Clin Mol Hepatol.
- 2024 Jan;30(1):124-125.
- doi: 10.3350/cmh.2023.0470
-
- CITED
-
- Close
- SHARE
-
- Close
- Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
-
Zhu Y, Ma X, Ni W, Yeo YH, Shi J, Li J
- KMID: 2560100
- Clin Mol Hepatol.
- 2024 Oct;30(4):974-977.
- doi: 10.3350/cmh.2024.0417
-
- CITED
-
- Close
- SHARE
-
- Close
- Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
-
Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, Nguyen MH
- KMID: 2534349
- Clin Mol Hepatol.
- 2022 Oct;28(4):841-850.
- doi: 10.3350/cmh.2022.0239
Background/Aims: Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD.... -
- CITED
-
- Close
- SHARE
-
- Close
- Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
-
Le MH, Le DM, Baez TC, Dang H, Nguyen VH, Lee K, Stave CD, Ito T, Wu Y, Yeo YH, Ji F, Cheung R, Nguyen MH
- KMID: 2554429
- Clin Mol Hepatol.
- 2024 Apr;30(2):235-246.
- doi: 10.3350/cmh.2023.0485
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is associated with a multitude of adverse outcomes. We aimed to estimate the pooled incidence of NAFLD-related adverse events. Methods: We performed a systematic review... -
- CITED
-
- Close
- SHARE
-
- Close
